Hepatitis B Infection clinical trials
39 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones look like a fit.
- Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
- Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
- A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
- Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
- Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
- Two-fraction HDR Monotherapy for Localized Prostate Cancer
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
- TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
- Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
- A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
- A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
- Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes
- A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
- Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
- Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
- HepB mAb19 in Individuals With Chronic Hepatitis B Infection
- Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
- Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
- A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Auto Stem Cell Transplant for Lymphoma Patients
- Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
- Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
- IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
- Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
- A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations
- Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis
- Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma
- Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
- Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
- Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “Hepatitis B Infection” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.